Hypertension, Pulmonary Clinical Trial
Official title:
Vasodilator Therapy and Exercise Tolerance in IPF Patients
Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.
Idiopathic pulmonary fibrosis (IPF) is recognized as a predominantly noninflammatory paradigm
of lung fibrosis, characterized by heterogeneous myofibroblast proliferation (usual
interstitial pneumonia [UIP]) and a poor clinical prognosis. To date no therapies have been
demonstrated in well-designed, randomized, controlled trials (RCT) to favorably influence
functional status or survival of IPF patients. The need for effective therapies for VA
patients with IPF is thus obvious and urgent.
The overall goal of this VA Merit Review clinical research is to generate rigorous
preliminary data for evaluation of a new and potentially effective therapy for IPF. The
established, combined Miami Veterans Affairs Medical Center (VAMC) - University of Miami (UM)
IPF program has participated productively in a number of clinical trials to assess new agents
for the therapy of IPF (e.g., interferon gamma-lb, imatinib mesylate, etanercept, bosentan).
Our program is uniquely qualified to enroll large numbers of IPF patients in clinical trials,
because of its large metropolitan population base (>5,000,000 people) and extensive referral
network throughout South and Central America. The Veteran population of South Florida (Dade,
Broward and Monroe Counties) is approximately 236,000 (U.S. Census Bureau). Of that number
39% are 65 years of age or older, making them at high risk for IPF. Because of its large
Veteran and civilian population base, international referral network and previous experience
as a "high enrollment center" in IPF clinical trials, the Miami VAMC-UM IPF program is
uniquely qualified to anticipate the role of a CSP lead center.
Our central hypothesis is that sildenafil, a vasodilator, will have a beneficial effect
compared to placebo on disease progression, defined as a significant change in the 6-minute
walk distance or dyspnea index, in patients with IPF.
Specifically, we will test effects of sildenafil on IPF patients' exercise tolerance and
level of dyspnea in a double blind, randomized, placebo controlled (one to one assignment)
pilot study. Upon completion of this trial, it will be possible to assess efficacy of
sildenafil on progression of disease in IPF and possibly introduce this agent into
translational practice. Our specific objectives are:
Specific Objectives 1: To assess the possible therapeutic benefit of a vasodilator,
sildenafil, on exercise tolerance in IPF patients.
The working hypothesis is that, compared to placebo, sildenafil will favorably affect rate of
decline from baseline in exercise capacity (6-minutes walk).
Specific Objective 2: To assess and compare changes from baseline in pre- and post-exercise
dyspnea in sildenafil and placebo control groups.
The working hypothesis is that application of this agent will lead to more sustained exercise
and a more favorable clinical outcome in addition to a decrease in the degree of limiting
dyspnea after exercise.
The application of vasodilator therapy in IPF is unique in that it directly targets key
pathophysiologic mechanisms of functional limitation: Increased pulmonary vascular resistance
and dyspnea due to exercise. This novel approach will have a significant impact on field,
because it promises both additional insight into mechanisms of disease and immediate
therapeutic options.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04095286 -
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
|
Phase 1 | |
| Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
| Completed |
NCT02191137 -
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
|
Phase 4 | |
| Completed |
NCT01959828 -
Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery
|
Phase 3 | |
| Withdrawn |
NCT01202045 -
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
|
N/A | |
| Completed |
NCT01121458 -
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
|
Phase 4 | |
| Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
| Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
| Terminated |
NCT00825266 -
Insulin Resistance in Pulmonary Arterial Hypertension
|
Phase 4 | |
| Terminated |
NCT00384865 -
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
|
Phase 2 | |
| Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
| Completed |
NCT02826252 -
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
|
N/A | |
| Completed |
NCT02545465 -
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
|
N/A | |
| Recruiting |
NCT04498299 -
Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
|
||
| Recruiting |
NCT02558582 -
Effect of Exercise Training in Patients With Pulmonary Hypertension
|
N/A | |
| Active, not recruiting |
NCT02562235 -
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 | |
| Completed |
NCT02755298 -
Chronic Clinical Effect of Acetazolamide
|
Phase 2/Phase 3 | |
| Completed |
NCT02576002 -
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
|
N/A | |
| Terminated |
NCT03043976 -
Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension
|
N/A | |
| Completed |
NCT01178073 -
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 |